DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer.
Peer-influenced content. Sources you trust. No registration required. This is HCN.